Genetic alterations of ARID1B have been recently recognized as one of the most common mendelian causes of intellectual disability and are associated with both syndromic and non-syndromic phenotypes. The ARID1B protein, a subunit of the chromatin remodeling complex SWI/SNF-A, is involved in the regulation of transcription and multiple downstream cellular processes. We report here the clinical, genetic, and proteomic phenotypes of an individual with a unique apparent de novo mutation of ARID1B due to an intragenic duplication. His neurodevelopmental phenotype includes a severe speech/language disorder with full scale IQ scores 78-98 and scattered academic skill levels, expanding the phenotypic spectrum of ARID1B 
endurance was also apparent in early childhood and has persisted. He had prolonged recovery times from illnesses, including several developmental regressions that lasted 2 or more months between ages 7-9 years, as well as two episodes of difficulty recovering from general anesthesia at 3 and 6 years old. Ophthalmologic exam revealed a right optic nerve pit. Growth parameters at 6.5 years included head circumference 54.8 cm (98%), weight 22.1 kg (52%), and height 116.9 cm (38%). Physical exam at 12.4 years showed a non-dysmorphic male with weight 36.6 kg (18%) and height 140.3 cm (7%); neurological exam showed slowed processing to questions or directions, abnormal gait with bilateral intoeing, mild imbalance, mild dysmetria, slow rapid alternating movements, and clumsy fine motor function.
The earliest neuropsychological assessment, at 3.5 years, used the Stanford Binet 5 tool and showed full-scale IQ 98, verbal IQ 122, and non-verbal IQ 74. At 5 years, using the WPPSI-III, he was noted to have a full-scale IQ 83, verbal IQ 78, and non-verbal IQ 96, a poor fund of general knowledge and difficulty formulating and expressing verbal concepts. At 8 years, using the WISC-4, there was a full-scale IQ 78, with verbal comprehension 85, perceptual reasoning 102, working memory 86, and processing speed 50. His strongest skills related to nonverbal visual-spatial reasoning. There was slow processing of information, deficiency of working memory, and poor visual/graphomotor skills. He was diagnosed with a severe language disorder. Auditory evaluation at 10 years showed an auditory processing disorder with severe difficulty in figure-ground discrimination, integration of words and sentences, temporal integration and phonological processing, and low average auditory comprehension, and average auditory short-term memory. At 12.5 years, using the Wide Range Achievement Test-4, he scored 101, 104, 91, and 67 in word reading, sentence comprehension, spelling, and math computation, respectively.
Cranial MRIs at 6 months and 7 years of age showed a mildly dysmorphic corpus callosum. A 48 hr EEG at 5 years was unremarkable.
Routine blood tests and urinalysis were normal. Normal metabolic testing included thyroid function tests, plasma amino acids, blood ammonia, and urinary organic acids, acylglycines, guanidinoacetate and creatine.
Newborn screening, including for galactosemia, was negative. A fasting global plasma metabolomic analysis was unremarkable. The blood lactate and plasma butyrylcarnitine levels were intermittently increased. The fibroblast lactate:pyruvate ratio was normal, as were activities of (version 9.5.3.1) and was analyzed using a web-based software platform (Cheung et al., 2005; Lu et al., 2007) . RSeQC (Wang, Wang, & Li, 2012) , and SamTools (Li et al., 2009 ).
| Transcriptome analysis
Novel transcript analysis was performed using Cufflinks, and FIGURE 1 Molecular and genetic characterization of the ARID1B microduplication. (a) Representation of the ARID1B transcripts expressed in the patient with exon numbering based on an Ensembl transcript ENST00000346085. (b) Array CGH shows the duplicated region comprising exons 2 to 10 between the vertical lines. (Green dots represent probes with log ratio above 0.2 and red dots those with log ratio below −0.2. Duplication or deletion is considered when probes are ≥0.4 or ≤−0.6, respectively.) (c) Sashimi plots generated from the RNAseq datasets depict the splice junctions that have a minimum of 3 reads supporting each junction. No novel junctions are observed in the patient. (d) FISH analysis (performed with a BAC clone, RP11-680A17, labeled in red and a control probe, RP11-719E16, labeled in green) confirms the duplication in interphase and metaphase cells, showing the duplication on chromosome 6 (as indicated by the white arrow) and not inserted into another chromosome. (e) (left to right) Decreased expression levels of ARID1B measured by qRT-PCR (using primers on exon 9 and on the junction of exons 10 and 11), in comparison to 7 age-and gender-matched controls (p-val 0.02), and by RNAseq in comparison to 5 age-matched controls. Error bars represent standard deviation. Transcript abundance analysis in the patient shows the 3 ARID1B expressed transcripts, measured from the RNAseq dataset using Cufflinks.
visualized on Integrative Genomics Viewer (Robinson et al., 2011; Thorvaldsdóttir, Robinson, & Mesirov, 2013 
| Quantitative RT-PCR
Quantitative RT-PCR was performed for ARID1B using custom designed primers and ACTB, GAPDH and POLR2A were used as endogenous controls. Primers were as described: 
| Proteome analysis
LCLs from the subject, obtained at 13 years of age, and 5 male controls ages 31-40 years were used. A total of 15 µg of protein from each sample was digested with LysC for 1 hr and trypsin overnight at 37°C.
Reverse phase LC-MS/MS was performed as described (Tomechko et al., 2015) , except that 600 ng of peptide digests was loaded on the HPLC column and the gradient of solvent B ranged from 2% to 40% over 210 min.
Raw LC-MS/MS data files for each sample were processed using Rosetta Elucidator (Rosetta Biosoftware, Seattle, WA) (Version 3.3.01 SP4 25). Automated differential quantification of peptides was performed as previously described (Azzam et al., 2016; Neubert et al., 2008; Schlatzer, Sugalski, Dazard, Chance, & Anthony, 2012) .
Briefly, LC-MS/MS raw data were imported, and for each MS spectrum profile of each LC-MS/MS run, chromatographic peaks, and monoisotopic masses were extracted and aligned. Chromatographic peaks were first aligned by retention time and monoisotopic mass. Peaklists with the monoisotopic mass and corresponding MS/MS data were then generated for each sample and searched using Mascot. Resultant peptide identifications were imported into Elucidator and monoisotopic masses annotated with peptide identifications. The false discovery rate for protein identifications was calculated to be 0.02%. The MS/MS peak lists were searched by Mascot (version 2.4.1) (Matrix Science, London, UK) using the human UniProt database.
Search settings were as follows: trypsin enzyme specificity; mass accuracy window for precursor ion, 25 ppm; mass accuracy window for fragment ions, 0.8 Da; variable modifications including carbamidomethlylation of cysteines, one missed cleavage and oxidation of methionine.
| Statistical methods and bioinformatic analyses
Raw MS data were obtained for each region in a csv file; this file contained intensity values, with rows corresponding to peptides and columns corresponding to the sample. Missing values were imputed using a weighted k-nearest neighbors algorithm (Troyanskaya et al., 2001 ). Next, data were log 2 -transformed to achieve normality. Data were visualized with principal component analysis and complete linkage hierarchical clustering. These preprocessing steps were performed using InfernoRDN (formerly DanTE) (Polpitiya et al., 2008) . Data were imported into the R statistical programming environment for subsequent analyses.
Because there was one case and multiple controls, we treated individual peptides as observations of a given protein. Therefore, proteins with only one quantified peptide were excluded from our analysis. To compare protein abundance between the case and controls, we constructed a linear mixed effects model that adjusted for subject to account for the non-independence of peptides derived from the same sample. Proteins with q < 0.01 were imported into DAVID version 6.8 (https://david.ncifcrf.gov/tools.jsp) for ontology analysis. EASE score threshold was set at a value of 1.0 and minimum count for an annotation term was set to 3. The entire set of proteins with more than one peptide (n = 2,351) was used as background for enrichment analysis. Network and pathway analyses were performed in Ingenuity Pathway Analysis (IPA®, www.qiagen.com/ ingenuity); proteins with q-value < 0.01 were used for this purpose.
Network connections were curated based on data from all species SEABRA ET AL.
| RESULTS
Measurement of ARID1B expression by quantitative RT-PCR showed a significant decrease of mRNA levels in the patient in comparison to control subjects (p-value 0.02) and a similar result was observed using RNAseq (Figure 1e ). Allele-specific expression could not be assessed since the subject was not heterozygous for SNPs located in coding exons or in the untranslated regions. The most abundant mRNA transcript observed in the RNAseq dataset was ENST00000414678, consistent with the GTEx database for EBV-transformed lymphoblasts; ENST00000350026 and ENST00000346085 were also detected in the patient sample (Figure 1e ). IGV Sashimi plots did not reveal novel junctions or transcripts for this gene (Figure 1c ), providing no evidence that duplication of this exonic region resulted in alterations in splicing.
Follow-up fluorescence in situ hybridization analyses showed the presence of duplicated ARID1B genome in interphase cells (Figure 1d ).
The latter, in turn, was localized to chromosome 6q25.3 on analysis of a metaphase cell, the site of the ARID1B gene (Figure 1d 
| DISCUSSION
The subject has a unique ARID1B mutation, a copy number gain involving part of that gene that was initially determined by a chromosomal microarray analysis and which was thought likely to cause a pathologic reduction of ARID1B gene expression. Subsequent gene expression data, by both qRT-PCR and RNAseq, indicated haploinsufficiency of ARID1B and was consistent with localization of the duplication within the ARID1B gene, disrupting expression of the affected allele. Confirmation that there is a large intragenic ARID1B duplication was established by a fluorescence in situ hybridization analysis. Haploinsufficiency for ARID1B is likely to be the cause of developmental delay in this individual as no additional genetic or metabolic defects were identified. While the measurement of RNA in LCLs does not necessarily reflect the effect of the genetic lesion in the brain, the association of heterozygous inactivating mutations in ARID1B with neurodevelopmental phenotypes in other subjects suggests that reduced gene expression also occurs in the central nervous system. As ARID1B is expressed at different levels in the brain, namely higher in the cerebellum than in many peripheral tissues and other measured areas of the brain (http://www.gtexportal.org/), the consequences of its reduced expression may be even more pronounced there, possibly accounting for aspects of subject's phenotype.
There are two reports of smaller microduplications of ARID1B. The clinical and genetic phenotypes of these two individuals and our case are summarized in Supplementary   Table S4 . Our case has several unique aspects to his phenotype.
Few individuals with ARIB1B haploinsufficiency are reported with low-normal intellectual function (Santen & Clayton-Smith, 2014 ).
Our patient, while having a significant speech/language disorder and cognitive disability, has had several IQ determinations within the normal range but there was considerable (and reproducible) variability in selected skills. In addition, his clinical course has been characterized by easy fatigability and episodes of developmental regression, prompting evaluation for a possible metabolic underpinning of these clinical concerns. Apart from intermittent elevated blood lactate levels, extensive metabolic testing was unrevealing. To our knowledge, other cases of individuals with ARID1B haploinsufficiency do not have histories of episodic regression, although the episodic memory dysfunction in one case may be relevant (Yu et al., 2015) .
Our results support the view that ARID1B is a dosage sensitive gene whose expression can be affected by deletions or duplications. Indeed, the evolutionary constraint on this gene shows that it is highly intolerant to loss-of-function mutations according to its ExAC pLI score of 1.00 (http://exac. broadinstitute.org/). As we did not identify novel transcripts, the duplicated allele either was not transcribed or was transcribed but its RNA was degraded by surveillance mechanisms.
Other chromatin regulators have also been noted to be dosage sensitive causes of neurodevelopmental phenotypes, including MBD5, EHMT1, CHD8, and SATB2 (Talkowski et al., 2012) .
The lymphoblast proteomic data are striking: statistically highly significant dysregulation of pathways related to initiation of translation were noted, in addition to dysregulation of pathways and networks relating to protein ubiquitination, mTOR signaling,
